scholarly article | Q13442814 |
P356 | DOI | 10.1007/S00103-017-2618-6 |
P698 | PubMed publication ID | 28879392 |
P2093 | author name string | German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute (RKI) | |
P2860 | cites work | Herpes zoster in Germany: quantifying the burden of disease | Q21261833 |
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860868 | ||
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults | Q28254168 | ||
Acute Pain in Herpes Zoster and Its Impact on Health-Related Quality of Life | Q28315858 | ||
Quantification of risk factors for herpes zoster: population based case-control study | Q28657403 | ||
Recent advances in varicella-zoster virus infection | Q33664545 | ||
Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany | Q33709036 | ||
Live vaccine used to prevent the spread of varicella in children in hospital | Q34202755 | ||
The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study | Q34273914 | ||
Herpes zoster recurrences more frequent than previously reported | Q34541849 | ||
Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years | Q34635527 | ||
Preherpetic neuralgia | Q34801625 | ||
Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany | Q35000186 | ||
Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy | Q35004161 | ||
Long-term persistence of zoster vaccine efficacy | Q35171857 | ||
Comparative biology of latent varicella-zoster virus and herpes simplex virus infections | Q35229927 | ||
Safety and tolerability of zoster vaccine in adults ≥60 years old. | Q35881283 | ||
Hospitalization with varicella and shingles before and after introduction of childhood varicella vaccination in Germany | Q35886434 | ||
Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy | Q35975369 | ||
Natural history and treatment of varicella-zoster in high-risk populations | Q36517653 | ||
Postherpetic neuralgia: epidemiology, pathophysiology and management | Q36998853 | ||
Pathogenesis and current approaches to control of varicella-zoster virus infections | Q37263293 | ||
Herpes Zoster Duplex Unilateralis: Two Cases and Brief Literature Review | Q37446829 | ||
Post-herpetic Neuralgia: a Review. | Q38734753 | ||
Post-herpetic neuralgia in older patients. Incidence and optimal treatment | Q39479867 | ||
Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years | Q40891715 | ||
Incidence of herpes zoster and its complications in Germany, 2005-2009. | Q42186997 | ||
Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany | Q42281395 | ||
Disseminated herpes zoster in patients with human immunodeficiency virus infection | Q44341271 | ||
Risk factors for postherpetic neuralgia in patients with herpes zoster | Q44891234 | ||
Seroprevalence of varicella-zoster virus in the German population | Q45735563 | ||
Transmission of varicella-vaccine virus from a healthy 12-month-old child to his pregnant mother | Q45761229 | ||
Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease | Q46082829 | ||
The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults | Q48464478 | ||
Demography, symptomatology, and course of disease in ambulatory zoster patients. A physician-based survey in Germany | Q56891583 | ||
P433 | issue | 10 | |
P921 | main subject | Germany | Q183 |
herpes zoster | Q182155 | ||
attenuated vaccine | Q1810913 | ||
P304 | page(s) | 1162-1179 | |
P577 | publication date | 2017-09-07 | |
P1433 | published in | Bundesgesundheitsblatt | Q1006114 |
P1476 | title | Background paper to the decision not to recommend a standard vaccination with the live attenuated herpes zoster vaccine for the elderly in Germany : Statement of the German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute (RKI) | |
P478 | volume | 60 |
Search more.